Skip to main content

Ginkgo Bioworks acquires Zymergen

Cell engineering company Ginkgo Bioworks has acquired the troubled synthetic biology specialist Zymergen for a market capitalisation of $300 million. It will now look for “strategic alternatives” for the new drug discovery business once this is complete. Both boards have approved.

Subscribe to Ginkgo Bioworks